RU2020124138A - Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы - Google Patents

Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы Download PDF

Info

Publication number
RU2020124138A
RU2020124138A RU2020124138A RU2020124138A RU2020124138A RU 2020124138 A RU2020124138 A RU 2020124138A RU 2020124138 A RU2020124138 A RU 2020124138A RU 2020124138 A RU2020124138 A RU 2020124138A RU 2020124138 A RU2020124138 A RU 2020124138A
Authority
RU
Russia
Prior art keywords
pyridin
amino
phenyl
pyrido
oxazin
Prior art date
Application number
RU2020124138A
Other languages
English (en)
Russian (ru)
Inventor
Йохан Линдстрём
Ларс Бухарта ПЕРССОН
Дженни ВИКЛУНД
Эдвард А. КЕСИКИ
Юджин Р. ХИКИ
Маркус К. ДАЛЬГРЕН
Алексей И. Герасюто
Original Assignee
Хиберселл, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хиберселл, Инк. filed Critical Хиберселл, Инк.
Publication of RU2020124138A publication Critical patent/RU2020124138A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
RU2020124138A 2017-12-22 2018-12-21 Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы RU2020124138A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609568P 2017-12-22 2017-12-22
US62/609,568 2017-12-22
PCT/US2018/067264 WO2019126731A1 (en) 2017-12-22 2018-12-21 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Publications (1)

Publication Number Publication Date
RU2020124138A true RU2020124138A (ru) 2022-01-24

Family

ID=65041934

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020124138A RU2020124138A (ru) 2017-12-22 2018-12-21 Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы

Country Status (11)

Country Link
US (2) US11667651B2 (enExample)
EP (1) EP3728228A1 (enExample)
JP (2) JP7569688B2 (enExample)
CN (1) CN112020500A (enExample)
AU (1) AU2018388404B2 (enExample)
BR (1) BR112020012635A2 (enExample)
CA (1) CA3085366A1 (enExample)
IL (1) IL275490B2 (enExample)
MX (1) MX2020006587A (enExample)
RU (1) RU2020124138A (enExample)
WO (1) WO2019126731A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
AU2018392816B2 (en) 2017-12-22 2023-04-20 HiberCell Inc. Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112441964A (zh) * 2019-08-27 2021-03-05 北京奥得赛化学股份有限公司 一种制备4-异丙基吡啶的新方法
CN111303195B (zh) * 2020-04-07 2022-09-27 中国医学科学院放射医学研究所 一类含硼小分子化合物、其制备方法及应用
CN112321494B (zh) * 2020-11-17 2022-04-19 上海凌凯医药科技有限公司 一种制备2-氯-4-异丙基吡啶的方法
CA3173777A1 (en) * 2021-05-20 2022-11-20 Dana-Farber Cancer Institute, Inc. Inhibitors and degraders of pip4k protein
TW202317106A (zh) * 2021-08-27 2023-05-01 南韓商柳韓洋行 作為egfr抑制劑之取代胺基吡啶化合物
TW202328096A (zh) 2021-08-27 2023-07-16 南韓商柳韓洋行 作為egfr抑制劑之含五員雜芳基之胺基吡啶化合物
EP4618755A1 (en) * 2022-11-15 2025-09-24 Larkspur Biosciences, Inc. Inhibitors and degraders of pip4k protein
WO2024236595A1 (en) * 2023-05-18 2024-11-21 Council Of Scientific And Industrial Research Protacs for ask1 protein degradation: preparation and use thereof

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
EP1690854A1 (en) 1999-03-12 2006-08-16 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
EP1466906A1 (en) 1999-03-12 2004-10-13 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
ID30176A (id) 1999-03-12 2001-11-08 Boehringer Ingelheim Pharma Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
AU773218B2 (en) 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
US6703525B2 (en) 2000-02-16 2004-03-09 Boehringer Ingelheim Pharmaceuticals, Inc. Sulfonamide intermediates and methods of producing same
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
EP1560584B1 (en) 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1381594A1 (en) 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. Urea compounds useful as anti-inflammatory agents
WO2002096876A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
EP1427412A1 (en) 2001-09-13 2004-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
AU2002341921B2 (en) 2001-10-04 2007-05-31 Merck Sharp & Dohme Corp. Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US20050101518A1 (en) 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
PL218692B1 (pl) 2002-01-22 2015-01-30 Warner Lambert Co Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek
JPWO2003062234A1 (ja) 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
WO2004030637A2 (en) 2002-10-01 2004-04-15 Merck & Co., Inc. Treatment of obesity and other disorders associated with excessive food intake
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
US20070027321A1 (en) 2003-09-02 2007-02-01 Kamenecka Theodore M Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
JP4946861B2 (ja) 2004-08-09 2012-06-06 アステラス製薬株式会社 ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物
ES2338590T3 (es) 2005-09-06 2010-05-10 Glaxosmithkline Llc Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
DE602006012694D1 (de) 2005-09-06 2010-04-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk-modulatoren
WO2007056023A2 (en) 2005-11-02 2007-05-18 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP1968972B1 (en) 2005-12-23 2012-11-28 F. Hoffmann-La Roche AG Aryl-isoxazolo-4-yl-oxadiazole derivatives
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007213018A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CN101384586A (zh) * 2006-02-14 2009-03-11 诺华公司 Pi-3激酶抑制剂及其应用方法
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US20100075960A1 (en) 2006-06-02 2010-03-25 Kevin Kuntz Benzimidazole thiophene compounds
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
WO2007146712A2 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
DE102007007751A1 (de) 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
CA2728016C (en) 2008-06-24 2017-02-28 F. Hoffmann-La Roche Ag Novel substituted pyridin-2-ones and pyridazin-3-ones
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
EP2321309A1 (en) 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
CN102203083A (zh) 2008-06-25 2011-09-28 Irm责任有限公司 作为激酶抑制剂的嘧啶衍生物
PE20110403A1 (es) 2008-07-31 2011-07-04 Genentech Inc Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
KR20120034592A (ko) 2009-04-09 2012-04-12 베링거 인겔하임 인터내셔날 게엠베하 Ｈｉｖ 복제의 저해제
KR101445458B1 (ko) 2009-06-04 2014-10-07 노파르티스 아게 １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체
CN102573486A (zh) 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
WO2011021678A1 (ja) 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
HUE027256T2 (en) 2010-09-13 2016-08-29 Novartis Ag Triazine-oxadiazoles
WO2012045124A1 (en) 2010-10-08 2012-04-12 Biota Europe Ltd Bacteria topoisomerase ii inhibiting 2-ethylcarbamoylamino-1, 3-benzothiazol-5-yls
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
CN102617548A (zh) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
JP2014513728A (ja) 2011-05-17 2014-06-05 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤としてのアザインドール誘導体
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
HUE036582T2 (hu) 2012-04-17 2018-07-30 Fujifilm Corp Nitrogéntartalmú heterociklusos vegyület vagy annak sója
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CA2884766A1 (en) 2012-10-16 2014-04-24 Daniel Jon Burdick Serine/threonine kinase inhibitors
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015098991A1 (ja) 2013-12-26 2015-07-02 東レ株式会社 Ｎ－アルキルアミド誘導体及びその医薬用途
WO2015112441A1 (en) 2014-01-22 2015-07-30 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
AU2015222865B2 (en) 2014-02-28 2019-06-20 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US10087195B2 (en) 2014-05-28 2018-10-02 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2016015604A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2016022644A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
EP3191467B1 (en) 2014-09-12 2020-10-21 Novartis AG Compounds and compositions as kinase inhibitors
JP6672296B2 (ja) 2014-10-31 2020-03-25 ザ ジェネラル ホスピタル コーポレイション 強力なγ−セクレターゼモジュレータ
WO2016089208A2 (en) 2014-12-04 2016-06-09 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
JP6884102B2 (ja) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
EP3053577A1 (en) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
ES2930585T3 (es) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
MX385083B (es) 2015-04-14 2025-03-14 Qurient Co Ltd Derivados de quinolina como inhibidores de tirosinas-cinasas de receptor de met de axl, mer y tyro 3 (tam rtk).
LT3305785T (lt) 2015-05-29 2021-11-10 Teijin Pharma Limited Pirido[3,4-d]pirimidino dariniai ir jų farmaciniu požiūriu priimtinos druskos
US10695346B2 (en) * 2015-06-26 2020-06-30 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
MX382671B (es) 2015-12-10 2025-03-13 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EP3386981B1 (en) 2015-12-13 2021-10-13 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as anti-cancer agents
AU2017232610B2 (en) 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
AU2017254708B2 (en) 2016-04-22 2021-09-16 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
CN109476635B (zh) 2016-04-29 2021-07-13 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN112250669B (zh) 2016-09-07 2022-02-25 江苏豪森药业集团有限公司 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
CA3058182A1 (en) 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Heterocyclic compound
KR102444482B1 (ko) 2017-04-01 2022-09-16 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN109516989B (zh) 2017-09-17 2021-12-31 上海美志医药科技有限公司 一类抑制并降解cdk的化合物
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2018392816B2 (en) 2017-12-22 2023-04-20 HiberCell Inc. Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2019216492A1 (en) 2018-02-02 2020-08-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
AU2019309909A1 (en) 2018-07-23 2021-02-04 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
BR122023024103A2 (pt) * 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
DK3877052T3 (da) * 2018-11-06 2023-09-25 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
WO2020109191A1 (en) 2018-11-27 2020-06-04 F. Hoffmann-La Roche Ag Aryl compounds for the treatment and prophylaxis of bacterial infection
US12415797B2 (en) 2018-11-30 2025-09-16 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound as CDK-HDAC double-channel inhibitor
US12358911B2 (en) 2018-12-07 2025-07-15 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
EP3891149A4 (en) 2018-12-07 2022-09-07 Sunshine Lake Pharma Co., Ltd. RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
AU2020204714A1 (en) 2019-01-04 2021-07-08 Praxis Biotech LLC Inhibitors of fibroblast activation protein
EP3920918A4 (en) 2019-02-05 2022-11-16 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
CN113661164B (zh) 2019-04-08 2025-03-04 珠海宇繁生物科技有限责任公司 一种cdk激酶抑制剂及其应用
CA3138973A1 (en) 2019-05-05 2020-11-12 Qilu Regor Therapeutics Inc. Cdk inhibitors
AU2020277027A1 (en) 2019-05-13 2021-12-09 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物

Also Published As

Publication number Publication date
IL275490A (en) 2020-08-31
US11667651B2 (en) 2023-06-06
IL275490B1 (en) 2024-01-01
MX2020006587A (es) 2020-12-10
IL275490B2 (en) 2024-05-01
BR112020012635A2 (pt) 2020-12-01
JP2021506978A (ja) 2021-02-22
JP2024056755A (ja) 2024-04-23
AU2018388404A1 (en) 2020-06-18
AU2018388404B2 (en) 2023-11-02
JP7569688B2 (ja) 2024-10-18
CN112020500A (zh) 2020-12-01
CA3085366A1 (en) 2019-06-27
US20240158415A1 (en) 2024-05-16
WO2019126731A1 (en) 2019-06-27
EP3728228A1 (en) 2020-10-28
US20210317136A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
RU2020124138A (ru) Производные аминопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
JP2024056755A5 (enExample)
US10669269B2 (en) Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
JP6203439B2 (ja) テトラヒドロピラニルメチル基を有するピリドン誘導体
US9181272B2 (en) Aldosterone synthase inhibitors
RU2020124136A (ru) Производные хроменопиридина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
AU2018294557A1 (en) Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
US12435062B2 (en) Amide compounds and uses thereof
KR20220024014A (ko) Acss2 저해제 및 이의 사용 방법
AU2014347026A1 (en) Substituted pyridine derivatives useful as GSK-3 inhibitors
CA2881638A1 (en) Pyridine derivative and medicine
KR102727682B1 (ko) 신규한 헤테로사이클릭 화합물
HK40058077A (en) Pyridone derivative having tetrahydropyranylmethyl group
HK40082804B (zh) 酰胺类化合物及其用途
HK1238630B (en) Pyridone derivative having tetrahydropyranyl methyl group
HK1238630A1 (en) Pyridone derivative having tetrahydropyranyl methyl group